ClinicalTrialsFinder
RecruitingNot ApplicableNCT06967194

Early Beta Blocker Administration in STEMI Patients With SCAI B Status

Early Beta-Blocker Administration in Patients With ST Segment Elevation Myocardial Infraction and SCAI B Status

Sponsor

Tel-Aviv Sourasky Medical Center

Enrollment

200 participants

Start Date

May 21, 2025

Study Type

INTERVENTIONAL

Summary

This study is looking at how a medication called beta-blockers (metoprolol) affects patients with a heart attack (STEMI) who are in the cardiac intensive care unit. When patients are admitted to the unit, they will be randomly placed in one of two groups. One group will get the metoprolol medication, and the other will receive a placebo (a harmless pill that looks like the real medication). All other treatments will be the same for both groups. During the study, which is 72 hours long, patients will be monitored for blood pressure, heart rate, and lactate levels alterations. The main goal is to see if the medication helps improve patients condition or prevent it from getting worse. patients safety is a top priority, and if needed, the doctors can stop the study at any time if there are concerns.

Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Diagnosis of ST-segment elevation myocardial infarction (STEMI) confirmed by ECG, clinical signs, and coronary catheterization.
  • Post-catheterization patients classified as SCAI B upon admission to the unit, defined by the presence of tachycardia and/or hypotension without signs of hypoperfusion (i.e., normal lactate levels, normal capillary refill, preserved mental status, and adequate urine output >0.5 mL/kg/hour).
  • Age 18 years or older.
  • Mentally competent to provide informed consent, understand the study procedures, and comply with medical recommendations.

Exclusion Criteria8

  • Pregnancy.
  • Inability to provide informed consent.
  • Evidence of pulmonary edema.
  • Bradycardia (heart rate <60 beats per minute).
  • PR interval >240 milliseconds.
  • Second- or third-degree atrioventricular (AV) block.
  • Active asthma.
  • Known hypersensitivity to metoprolol.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMetoprolol (MET)

Administration of metoprolol 25 mg twice daily

DRUGPlcacebo

Administration of matching placebo

Locations(1)

Tel Aviv Sourasky Medical center

Tel Aviv, Israel

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06967194